Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE.

Clin Infect Dis. 2010 Jan 15;50(2):184-91. doi: 10.1086/649209.

PMID:
20001736
2.

Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.

Poland GA.

Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S45-53. doi: 10.1086/648964. Review.

PMID:
20144016
3.

Prevention of meningococcal disease.

Kimmel SR.

Am Fam Physician. 2005 Nov 15;72(10):2049-56. Review.

4.

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

Noronha CP, Struchiner CJ, Halloran ME.

Int J Epidemiol. 1995 Oct;24(5):1050-7.

PMID:
8557439
5.

Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA; Active Bacterial Core surveillance (ABCs) team.

Vaccine. 2001 Aug 14;19(31):4566-75.

PMID:
11483285
6.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

PMID:
18171206
7.

Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team.

Pediatrics. 2005 May;115(5):1220-32.

PMID:
15867028
8.

Optimizing protection against meningococcal disease.

Reisinger KS, Black S, Stoddard JJ.

Clin Pediatr (Phila). 2010 Jun;49(6):586-97. doi: 10.1177/0009922809354327. Epub 2010 Jan 20. Review.

PMID:
20089551
9.

Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.

Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE.

Clin Infect Dis. 2006 Jul 1;43(1):49-54. Epub 2006 May 24.

PMID:
16758417
11.

Meningococcal disease and vaccination in North America.

Pollard AJ, Scheifele D.

J Paediatr Child Health. 2001 Oct;37(5):S20-7.

PMID:
11885732
12.

Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.

Pace D.

Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Review.

PMID:
19397410
13.

Prevention of meningococcal disease.

Woodard JL, Berman DM.

Fetal Pediatr Pathol. 2006 Nov-Dec;25(6):311-9. Review.

PMID:
17696042
14.

The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004.

O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, Van Beneden C; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2007 Oct 1;45(7):853-62. Epub 2007 Aug 29.

PMID:
17806049
15.

Meningococcal disease.

Memish ZA, Alrajhi AA.

Saudi Med J. 2002 Mar;23(3):259-64. Review.

PMID:
11938412
16.

The changing epidemiology of meningococcal disease in the United States, 1992-1996.

Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL.

J Infect Dis. 1999 Dec;180(6):1894-901.

PMID:
10558946
17.

Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.

Cardeñosa N, Domínguez A, Martínez A, Alvarez J, Pañella H, Godoy P, Minguell S, Camps N, Vázquez JA; Working Group on Meningococcal Disease.

Infection. 2003 Dec;31(6):392-7.

PMID:
14735381
18.

Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96.

Campagne G, Schuchat A, Djibo S, Ousséini A, Cissé L, Chippaux JP.

Bull World Health Organ. 1999;77(6):499-508.

19.

The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT).

Pediatr Infect Dis J. 2009 Mar;28(3):220-4. doi: 10.1097/INF.0b013e31819040e7.

PMID:
19209096
20.

Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China.

Ni JD, Jin YH, Dai B, Wang XP, Liu DQ, Chen X, Zheng Y, Ye DQ.

Postgrad Med J. 2008 Feb;84(988):87-92. doi: 10.1136/pgmj.2007.065680.

PMID:
18322129

Supplemental Content

Support Center